Literature DB >> 533881

Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues.

T K Schaaf, H J Hess.   

Abstract

A series of PGE2, 16,16-dimethyl-PGE2, and PGF2 alpha analogues modified at the carboxyl terminus with tetrazole, amide, acylurea, imide, and sulfonimide functionalities was evaluated for uterine stimulant, bronchodilator, hypotensive, gastric antisecretory, and diarrheal activity. These compounds were prepared by modification of the Corey prostaglandin synthesis utilizing as a key step condensation of known hemiacetals with the ylide derived from the requisite substituted phosphonium salts. Structure--activity relationships suggest that a proton at the C-1 position appears necessary for agonist activity and the acidity of this proton has a relatively greater influence on activity than pendant steric bulk. Noteworthy are the tissue-selective bronchodilator activity of N-acetyl-PGE2-carboxamide and the selectivity for uterine tissue of N-methanesulfonyl-PGE2-carboxamide, 2-decarboxy-2-(tetrazol-5-yl)-16,16-dimethyl-PGE2, N-acetyl-16,16-dimethyl-PGE2-carboxamide, and N-methanesulfonyl-16,16-dimethyl-PGE2-carboxamide.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 533881     DOI: 10.1021/jm00197a012

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

Review 1.  Prostaglandin E2 modulation of blood pressure homeostasis: studies in rodent models.

Authors:  Christina E Swan; Richard M Breyer
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-07-27       Impact factor: 3.072

2.  Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds.

Authors:  D F Woodward; A H Krauss; J Chen; D W Gil; K M Kedzie; C E Protzman; L Shi; R Chen; H A Krauss; A Bogardus; H T Dinh; L A Wheeler; S W Andrews; R M Burk; T Gac; M B Roof; M E Garst; L J Kaplan; G Sachs; K L Pierce; J W Regan; R A Ross; M F Chan
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

3.  Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK.

Authors:  Eugénie Goupil; Veronica Wisehart; Etienne Khoury; Brandon Zimmerman; Sahar Jaffal; Terence E Hébert; Stéphane A Laporte
Journal:  Mol Endocrinol       Date:  2012-05-25

4.  Novel tail and head group prostamide probes.

Authors:  David F Finnegan; Erin L Shelnut; Spyros P Nikas; Nan Chiang; Charles N Serhan; Alexandros Makriyannis
Journal:  Bioorg Med Chem Lett       Date:  2015-02-04       Impact factor: 2.823

5.  Effects of acetylenic epoxygenase inhibitors on recombinant cytochrome p450s.

Authors:  Melissa A VanAlstine; Lindsay B Hough
Journal:  Drug Metab Dispos       Date:  2011-04-01       Impact factor: 3.922

Review 6.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

7.  EP1 disruption attenuates end-organ damage in a mouse model of hypertension.

Authors:  Christina S Bartlett; Kelli L Boyd; Raymond C Harris; Roy Zent; Richard M Breyer
Journal:  Hypertension       Date:  2012-09-24       Impact factor: 10.190

Review 8.  Prostamides (prostaglandin-ethanolamides) and their pharmacology.

Authors:  D F Woodward; Y Liang; A H-P Krauss
Journal:  Br J Pharmacol       Date:  2007-08-27       Impact factor: 8.739

9.  Synthesis of 2-oxoamides based on sulfonamide analogs of gamma-amino acids and their activity on phospholipase A2.

Authors:  Georgia Antonopoulou; Victoria Magrioti; Daren Stephens; Violetta Constantinou-Kokotou; Edward A Dennis; George Kokotos
Journal:  J Pept Sci       Date:  2008-10       Impact factor: 1.905

10.  Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and Mice.

Authors:  Yuling Chi; Jean-Francois Jasmin; Yoshinori Seki; Michael P Lisanti; Maureen J Charron; David J Lefer; Victor L Schuster
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.